Suppr超能文献

钙调磷酸酶抑制剂对肾移植受者人体测量学指标的影响。

The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients.

机构信息

Departments of Nephrology, Uludag University Faculty of Medicine, Bursa, Turkey.

Present address: Department of Nephrology, Ufuk University School of Medicine Dr. Ridvan Ege Hospital, Mevlana Blv. No: 86-88, Balgat, Ankara, 06830, Turkey.

出版信息

BMC Nephrol. 2022 Nov 19;23(1):375. doi: 10.1186/s12882-022-03004-1.

Abstract

BACKGROUND

This study was designed to investigate the effect of calcineurin inhibitors (CNIs), cyclosporine (CsA), and tacrolimus (Tac) on anthropometrics in kidney transplant recipients.

METHODS

111 of 128 adult kidney transplant recipients who received post-transplant CNIs were included in this retrospective study. Anthropometrics were recorded in the pre-transplant and post-transplant 4-year follow-up periods (1, 3, 6, 12, 24, 36 and 48 months).

RESULTS

Compared to pre-transplant values, significant increases in body weight and body mass index (between 3 and 48 months), waist and hip circumferences (between 1 and 48 months), waist-to-hip ratio (between 1 and 3 or 6 months) and neck circumference (between 1 and 12 or 24 months) were observed in both CsA and Tac groups. A significant increase was noted in post-transplant body fat percentage values for the 3 to 24 months in the CsA group, whereas for the 24 to 48 months in both CsA and Tac groups. Hip circumferences percentage changes from the pre-transplant period to the 1, 12 and 24 months were significantly higher in CsA than in the Tac group. At each time point, there was no significant difference in percentage changes for other anthropometric parameters between the CsA and Tac groups. De novo diabetes mellitus developed in 8.3% of the CsA group and 19.1% of the Tac group.

CONCLUSIONS

After a successful kidney transplant, anthropometric measurements increase in most recipients. Although the effect of calcineurin inhibitor type on weight gain is unclear, a regression analysis showed that CNI type was not a risk factor for the development of obesity in the 48 month. However, it is helpful to be cautious about its dyslipidemic effect in patients using CsA and the potential hazards of using Tac in patients with a diabetic predisposition.

摘要

背景

本研究旨在探讨钙调磷酸酶抑制剂(CNI)环孢素(CsA)和他克莫司(Tac)对肾移植受者人体测量学的影响。

方法

本回顾性研究纳入了 128 例成年接受移植后 CNI 的肾移植受者中的 111 例。在移植前和移植后 4 年的随访期间(1、3、6、12、24、36 和 48 个月)记录人体测量学指标。

结果

与移植前相比,CsA 和 Tac 组在 3 至 48 个月时体重和体重指数(BMI)显著增加(3 至 48 个月),腰围和臀围(1 至 48 个月),腰臀比(1 至 3 或 6 个月)和颈围(1 至 12 或 24 个月)均增加。CsA 组在移植后 3 至 24 个月的体脂百分比显著增加,而 CsA 和 Tac 组在 24 至 48 个月时均增加。CsA 组从移植前到 1、12 和 24 个月的臀围百分比变化明显高于 Tac 组。在每个时间点,CsA 和 Tac 组之间的其他人体测量参数的百分比变化没有显著差异。CsA 组的新发糖尿病发病率为 8.3%,Tac 组为 19.1%。

结论

肾移植成功后,大多数受者的人体测量值增加。虽然钙调神经磷酸酶抑制剂类型对体重增加的影响尚不清楚,但回归分析表明,CNI 类型不是 48 个月肥胖发生的危险因素。然而,在使用 CsA 的患者中注意其脂代谢异常作用以及在有糖尿病倾向的患者中使用 Tac 的潜在危害是有帮助的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5c2/9675959/6ee6074a2da9/12882_2022_3004_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验